27 Apr 2024 • The AZTEC trial debunked the long-standing belief that azithromycin prophylaxis could mitigate chronic lung disease (CLD) in preterm infants born before 30 weeks’ gestation.

Despite prior conjecture, the study, spanning 28 neonatal intensive care units revealed that administering azithromycin did not improve survival without the development of physiologically-defined CLD, regardless of Ureaplasma spp colonization.

Since prophylactic use of azithromycin did not improve survival without development of physiologically-defined CLD, regardless of Ureaplasma spp colonisation, it cannot be recommended in clinical practice.

Source: The Lancet | Read full story